Therapy Areas: Diabetes
Therapeutic Solutions International Granted Landmark United States Patent on Ability of QuadraMune Nutraceutical to Repair Injured Brains
12 October 2022 - - US-based Therapeutic Solutions International has received a "Notice of Allowance" from the United States Patent and Trademark Office for its patent entitled "Neuroprotection and Neuroregeneration by Pterostilbene and Compositions Thereof," the company said.

The patent covers protection of brain cells, as well as stimulation of brain repair, using ingredients in QuadraMune and variations of the ingredients.

The company has previously demonstrated synergy between the ingredients in this nutraceutical. This is the third patent being granted on QuadraMune, which is commercially available from numerous sources, including on Amazon.

The first patent covered the use of QuadraMune for immune modulation in cancer and COVID-192. The second covered prevention and treatment of COVID-193 by QuadraMune administration.

Previously the company has shown that QuadraMune can increase the ability of natural killer cells to kill target cells, which is an important part of the body's defense mechanisms to viruses and cancer. Interestingly, addition of the diabetes drug metformin increased activity of QuadraMune.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.
Login
Username:

Password: